Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04364763 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
A Phase 2 study, sponsored by Renibus Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT04364763 is a Phase 2 study that was terminated before completion, run by Renibus Therapeutics. The registered enrollment target is 42 participants.
The verdict
NCT04364763, a Phase 2 study, was terminated before completion, sponsored by Renibus Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically ill adults who are at high risk of progression.
Interventions
- DRUG 0.9% sodium chloride (normal saline)
- DRUG RBT-9 (90 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04364763
The ClinicalTrials.gov registry entry for NCT04364763 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renibus Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% sodium chloride (normal saline) is the first listed.
NCT04364763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04364763 about?
NCT04364763 is a clinical study titled "A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)". The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically ill adults who are at high risk of progression.
What is the current status of trial NCT04364763?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-08-05. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04364763?
The interventions under investigation include: 0.9% sodium chloride (normal saline) (DRUG), RBT-9 (90 mg) (DRUG).
Who is sponsoring clinical trial NCT04364763?
This trial is sponsored by Renibus Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.